FDA issues CRL to small Dutch biotech's breast cancer ADC as OS figures fail to impress
The FDA has batted back an application for a potential breast cancer therapy.
US regulators issued a complete response letter to the small Dutch biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
